Reports Q4 revenue $174.2M, consensus $155.25M. “Our 2024 results reflect solid commercial execution across the company, including continued growth of our core products, and strong growth in operating earnings,” said Jack Khattar, President and CEO of Supernus (SUPN). “In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson’s disease, planned for the second quarter of 2025; and further advancement of our product pipeline.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus Pharmaceuticals Updates Executive Compensation Packages
- SUPN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cantor downgrades Supernus on ‘disappointing’ depression study
- Supernus downgraded to Neutral from Overweight at Cantor Fitzgerald
- Closing Bell Movers: Shift4 down 10%, Penumbra up 8% after results